Gilead Sciences Inc (GILD)
66.14
-0.80
(-1.20%)
USD |
NASDAQ |
Apr 18, 16:00
66.49
+0.35
(+0.53%)
After-Hours: 19:52
Gilead Sciences Accounts Receivable (Quarterly): 4.66B for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 4.66B |
September 30, 2023 | 4.79B |
June 30, 2023 | 4.229B |
March 31, 2023 | 4.162B |
December 31, 2022 | 4.777B |
September 30, 2022 | 4.354B |
June 30, 2022 | 4.118B |
March 31, 2022 | 3.787B |
December 31, 2021 | 4.493B |
September 30, 2021 | 4.566B |
June 30, 2021 | 4.149B |
March 31, 2021 | 3.925B |
December 31, 2020 | 4.892B |
September 30, 2020 | 3.913B |
June 30, 2020 | 3.194B |
March 31, 2020 | 3.907B |
December 31, 2019 | 3.582B |
September 30, 2019 | 3.315B |
June 30, 2019 | 3.396B |
March 31, 2019 | 3.283B |
December 31, 2018 | 3.327B |
September 30, 2018 | 3.465B |
June 30, 2018 | 3.541B |
March 31, 2018 | 3.775B |
December 31, 2017 | 3.851B |
Date | Value |
---|---|
September 30, 2017 | 4.122B |
June 30, 2017 | 4.478B |
March 31, 2017 | 4.034B |
December 31, 2016 | 4.514B |
September 30, 2016 | 5.075B |
June 30, 2016 | 5.752B |
March 31, 2016 | 6.163B |
December 31, 2015 | 5.854B |
September 30, 2015 | 6.105B |
June 30, 2015 | 5.331B |
March 31, 2015 | 4.835B |
December 31, 2014 | 4.635B |
September 30, 2014 | 2.850B |
June 30, 2014 | 3.437B |
March 31, 2014 | 3.236B |
December 31, 2013 | 2.182B |
September 30, 2013 | 1.972B |
June 30, 2013 | 1.896B |
March 31, 2013 | 1.945B |
December 31, 2012 | 1.751B |
September 30, 2012 | 1.766B |
June 30, 2012 | 1.703B |
March 31, 2012 | 2.164B |
December 31, 2011 | 1.951B |
September 30, 2011 | 1.867B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
3.194B
Minimum
Jun 2020
4.892B
Maximum
Dec 2020
4.116B
Average
4.149B
Median
Jun 2021
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 7.268B |
Johnson & Johnson | 14.87B |
Eli Lilly and Co | 9.090B |
CymaBay Therapeutics Inc (DELISTED) | -- |
Arcus Biosciences Inc | 38.00M |